

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

MESO: QuickPlex SQ 120

RRID:SCR_020304

Type: Tool

Proper Citation

MESO: QuickPlex SQ 120 (RRID:SCR_020304)

Resource Information

URL: <https://www.mesoscale.com/en/products/meso-quickplex-sq-120-ai0aa/>

Proper Citation: MESO: QuickPlex SQ 120 (RRID:SCR_020304)

Description: QuickPlex instrument is the newest multiplexing instrument from MSD, offering access to high-performance, electrochemiluminescence immunoassays. This compact system has been engineered for reliability, ease of use, and low cost of ownership. The combination of rapid read times and the ability to perform multiple, simultaneous tests on a single sample increases productivity, saves sample, and delivers results quickly. The QuickPlex has a wide menu of commercially available assay kits and a full line of components and reagents for developing your own assays.

Resource Type: instrument resource

Keywords: Multiplexing instrument, MSD, instrument, equipment, USEDit

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_020304.pdf

Resource Name: MESO: QuickPlex SQ 120

Resource ID: SCR_020304

Alternate IDs: Model_Number_SQ 120

Record Creation Time: 20220129T080349+0000

Record Last Update: 20260801T190647+0000

Ratings and Alerts

No rating or validation information has been found for MESO: QuickPlex SQ 120.

No alerts have been found for MESO: QuickPlex SQ 120.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang A, et al. (2026) Nonglycosylated, Legumain-Cleavable ISACs Drive Potent Antitumor Immunotherapy via a Bystander Effect. *Molecular cancer therapeutics*, 25(4), 622.

DePuyt AE, et al. (2026) Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset. *bioRxiv : the preprint server for biology*.

Aggarwal R, et al. (2025) Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3854.

Puzio-Kuter AM, et al. (2025) Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. *Cancer discovery*, 15(6), 1159.

Rastogi S, et al. (2025) Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation. *Cancer research communications*, 5(4), 668.

Watanabe Y, et al. (2023) Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours. *British journal of cancer*, 128(5), 886.

Whittaker DS, et al. (2023) Circadian modulation by time-restricted feeding rescues brain pathology and improves memory in mouse models of Alzheimer's disease. *Cell metabolism*, 35(10), 1704.

Sullivan KA, et al. (2022) Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice. *Brain, behavior, and immunity*, 99, 106.

Konno H, et al. (2022) ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models. *Cancer research communications*, 2(9), 937.

Brosseron F, et al. (2022) Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. *Neuron*, 110(6), 1009.

Jia X, et al. (2022) Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children. *The Journal of clinical endocrinology and metabolism*, 107(7), 1825.